A ma­jor­i­ty of phar­ma and biotech com­pa­nies pro­hib­it Chat­G­PT use, sur­vey finds

Most phar­ma and biotech com­pa­nies ban or re­strict the use of Chat­G­PT by their em­ploy­ees, ac­cord­ing to a re­cent sur­vey. Half of phar­ma and biotech com­pa­nies re­strict its use, but that jumps to 65% when nar­rowed down to the top 20 phar­ma com­pa­nies, ac­cord­ing to the Zoom­Rx sur­vey.

The chief rea­son cit­ed by al­most all was se­cu­ri­ty and the po­ten­tial to leak in­ter­nal da­ta. But the phar­ma in­dus­try isn’t alone in its con­cerns over the open, gen­er­a­tive AI plat­form. Many lead­ing tech and fi­nance brands, in­clud­ing Ap­ple, Ama­zon, Cit­i­group, Gold­man Sachs, JP­Mor­gan Chase, Mi­crosoft, Sam­sung and Ver­i­zon, have banned the in­ter­nal use of Chat­G­PT.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER